INTRODUCTION
============

Chronic right ventricular (RV) pacing could deteriorate left ventricular (LV) systolic function and increase mortality via pacing-induced electrical and mechanical dyssynchrony,[@B1][@B2][@B3][@B4][@B5] particularly in patients with pre-existing LV systolic dysfunction (LVSD).[@B1][@B6][@B7] However, even in patients without underlying LVSD, chronic RV pacing can cause new-onset LVSD, which can be defined as pacing-induced cardiomyopathy (PiCM).[@B3][@B8]

Cardiac resynchronization therapy (CRT) corrects electro-mechanical dyssynchrony and is now established as a standard treatment for advanced heart failure (HF) patients with a pacemaker (upgrade CRT) or without a pacemaker (*de novo* CRT).[@B9][@B10][@B11] However, it remains unclear whether upgrade CRT shows better outcomes than *de novo* CRT,[@B12][@B13][@B14][@B15] and no previous studies have investigated underlying LV function before pacemaker implantation in patients receiving upgrade CRT.[@B12][@B13][@B14][@B15]

We hypothesized that the efficacy of CRT would be greater in patients with PiCM (upgrade CRT for PiCM) than in those without PiCM (upgrade CRT for non-PiCM) or those treated by *de novo* implantation (*de novo* CRT). Therefore, this study aimed to compare the effect of CRT between the upgrade and *de novo* CRT groups, as well as between the PiCM upgrade and non-PiCM upgrade groups.

MATERIALS AND METHODS
=====================

Patients and baseline assessment
--------------------------------

We enrolled consecutive patients who received CRT at our center from March 2012 to July 2015. Patients with 1) drug-refractory advanced HF with New York Heart Association (NYHA) class III or ambulatory IV, 2) LV ejection fraction (LVEF) \<35%, and 3) QRS duration \>120 ms were included. Exclusion criteria included 1) switching off the CRT device within 3 months or 2) a follow-up duration of less than 3 months after implantation.

PiCM was defined when all of the following criteria were met: 1) LVEF prior to permanent pacemaker (PPM) insertion ≥50%, 2) new-onset LVSD (LVEF \<35%) in pacing-dependent (\>90% RV pacing)[@B16] patients, and 3) the absence of other causes of HF, including previous myocardial infarction, valvular heart disease, tachycardia-induced cardiomyopathy, toxic (alcohol or chemotherapy) cardiomyopathy, hypertensive cardiomyopathy, myocarditis, or other infiltrative diseases. All CRT upgrade patients who did not fulfil the criteria for PiCM were classified into non-PiCM. We categorized the patients into three groups: PiCM-upgrade, non-PiCM upgrade, and *de novo* CRT ([Fig. 1](#F1){ref-type="fig"}).

Baseline information, such as NYHA functional class and echocardiographic and electrocardiographic (ECG) parameters, was collected in all patients. Echocardiographic parameters included LVEF, end-diastolic dimension (LVEDD), end-systolic dimension (LVESD), end-diastolic volume (LVEDV), and end-systolic volume (LVESV). Additionally, pre-PPM LVEF was investigated in the upgrade CRT groups. ECG parameters encompassed the duration and morphology of the QRS complex. The baseline QRS morphology was categorized as left bundle branch block (LBBB) when all of the following criteria were met: 1) QRS duration \>120 ms, 2) QS or rS in lead V1, and 3) monophasic R wave with no Q wave in lead V6 and I; paced QRS complexes in the upgrade groups and native QRS complexes in the *de novo* group were used for this classification. We also investigated HF duration, defined as the time interval between the first time a patient received diuretics or vasodilator/inotropic therapy for HF symptoms of congestion and/or low cardiac output and CRT implantation. The Institutional Review Board at Samsung Medical Center approved the study protocol and waived the requirement for informed consent.

Device therapy
--------------

CRT implantation was performed under local anesthesia using a transvenous approach. The LV lead was preferably placed into the anterolateral, lateral cardiac veins, or posterolateral ventricular veins. An epicardial LV lead was screwed into the lateral mid-LV segment via thoracoscopic surgery unless the transvenous approach via the coronary sinus was successful. The position of the RV or LV lead was confirmed by left and right anterior oblique fluoroscopic images. RV lead positions were classified as apical or septal. LV lead positions were classified as basal, mid, or apical in the right anterior oblique view and as anterior, anterolateral, lateral, posterolateral, or posterior in the left anterior oblique view.[@B17] After implantation, atrioventricular and ventriculo-ventricular delays were determined showing the greatest stroke volume (Doppler-guided) or narrowest QRS duration (ECG-based) before discharge.

Follow-up assessment and outcomes
---------------------------------

The primary outcome was electrical and mechanical reverse remodeling evaluated at 6 months after CRT implantation. For assessment of electrical reverse remodeling, absolute \[(pre-CRT-post-CRT)\] and relative \[(pre-CRT-post-CRT)/pre-CRT×100, %\] change in the QRS duration was calculated. In a similar way, absolute and relative changes in LVESD, LVEDD, LVESV, LVEDV, and LVEF were calculated for mechanical reverse remodeling.

Secondary outcomes included improvement in symptoms assessed by change in NYHA class, responder rate, and long-term clinical outcomes. CRT responders were defined as follows: 1) 'clinical responder' for patients with any improvement in NYHA class, 2) 'echocardiographic responder' for patients with a relative decrease in LVESV by ≥15%, and 3) 'super-responder' for those with any improvement in NYHA class and a relative decrease in LVESV by ≥30%. Super-response rates were also assessed according to LVEF criteria as follows: 1) LVEF increase ≥fourth quartile or 2) LVEF ≥45% at 6 months after CRT.

Long-term clinical outcomes were assessed at the last follow-up in terms of all-cause death, cardiac death, heart transplantation, HF-related rehospitalization, and major adverse cardiac events (MACEs), encompassing cardiac death, heart transplantation, and HF-related rehospitalization.

Statistical analysis
--------------------

Continuous variables are presented as medians with interquartile ranges and categorical variables are presented as numbers with percentages. Comparisons between groups were performed using chi-square tests, Mann-Whitney U tests, or Kruskal-Wallis tests, as appropriate. Survival free from adverse clinical outcomes was estimated by Kaplan-Meier curve and compared by log rank test. A Cox proportional hazard model was used to assess the risk factors for clinical composite events, and the logistic regression method was used to determine the predictors of a super-responder. Variables for which the *p* value was \<0.2 were included in multivariate analysis. Statistical analyses were performed with the IBM SPSS Statistics version 23 (IBM Corporation, Armonk, NY, USA). All tests were two-tailed, and a *p* value\<0.05 was considered statistically significant.

RESULTS
=======

Patients and baseline characteristics
-------------------------------------

We identified 82 patients who underwent a CRT procedure during the enrollment period. Five of these patients were excluded because of the following reasons: two patients (one patient in the non-PiCM upgrade and one in the *de novo* group) were followed for less than 3 months, one patient (*de novo* group) died after the CRT procedure during the admission period, and two patients (*de novo* group) had their CRT devices turned off due to worsening HF symptoms. Of the remaining 77 patients, 62 underwent *de novo* implantation of CRT devices (*de novo* group), and 15 had their old PPM replaced by a CRT device (upgrade group). Indications for a pacemaker and RV pacing burden in CRT upgrade patients are summarized in [Supplementary Table 1](#S1){ref-type="supplementary-material"} (only online). Among the 15 patients in the upgrade group, seven met the criteria for PiCM, showing normal LVEF before PPM insertion and no definite cause of LVSD before CRT implantation (the PiCM upgrade group), while the remaining eight had reduced LVEF prior to PPM insertion (the non-PiCM upgrade group) ([Fig. 1](#F1){ref-type="fig"}).

There were no differences in baseline demographic characteristics among the groups. For echocardiographic findings, the non-PiCM upgrade group showed the highest median LVEF, while LV volumes were greatest in the *de novo* group. QRS duration in both upgrade groups was significantly longer than that in the *de novo* group, and LBBB morphology tended to be more frequent in the upgrade groups. Most patients in all three groups had their LV leads in lateral (anterolateral, lateral, or posterolateral) LV segments ([Table 1](#T1){ref-type="table"}).

Primary outcomes
----------------

[Fig. 2](#F2){ref-type="fig"} and the [Supplementary Table 2](#S2){ref-type="supplementary-material"} (only online) show the primary outcomes. The percent decrease in QRS duration was greatest in the PiCM upgrade group (26.8% vs. 21.4% vs. 19.0%, *p*=0.025). The percent reduction in LVESV was significantly greater in the PiCM upgrade group than in the other two groups at 6-month follow-up (46.2% vs. 9.4% vs. 18.1%, *p*=0.022).

Secondary outcomes
------------------

The PiCM upgrade group showed the highest responder rates, although the clinical and echocardiographic responder rates at 6 month did not reach statistical significance ([Table 2](#T2){ref-type="table"}, [Fig. 3](#F3){ref-type="fig"}). Especially, the super-responder rate was remarkably higher in the PiCM upgrade than the other groups (6.9 and 2.6 times higher than in the non-PiCM upgrade and *de novo* group, respectively). The super-response rates according to LVEF criteria were also highest in the PiCM upgrade group ([Fig. 3](#F3){ref-type="fig"}). On univariate and multivariate analyses, the PiCM upgrade group showed a significant association with super-responders (odds ratio 10.4, 95% confidence interval 1.08--99.4, *p*=0.043) ([Table 3](#T3){ref-type="table"}).

Patients underwent follow-up for a median of 15.8 (7.4--21.6) months, with no significant differences in follow-up duration among the groups. However, the PiCM upgrade group showed a tendency toward more favorable outcomes in terms of MACEs, compared to the other patient groups (*p*=0.059) ([Fig. 4](#F4){ref-type="fig"}). More detailed clinical outcomes are summarized in [Supplementary Table 3](#S3){ref-type="supplementary-material"} and [Supplementary Fig. 1](#S4){ref-type="supplementary-material"} (only online).

DISCUSSION
==========

In this study, PiCM upgrade was associated with more favorable outcomes with regard to electrical and mechanical reverse remodeling. Furthermore, PiCM upgrade was an independent predictor of CRT super-response. Survival analysis showed that clinical outcomes tended to be better in the PiCM upgrade group than the other groups.

Previous studies comparing the efficacy of CRT between upgrade and *de novo* groups showed conflicting results.[@B12][@B13][@B14][@B15] In a prospective observational study including 135 CRT cases, the authors showed that upgrade CRT had more favorable outcomes than *de novo* CRT over a period of 4 years in terms of death, heart transplantation, or LV assist devices.[@B15] However, no significant differences were observed in functional class change, QRS narrowing, and mortality at 1-year follow-up in the European CRT Survey, which compared 692 cases of upgrade CRT against 1675 of *de novo* CRT.[@B14] This conflicting data might result from the fact none of the previous researchers specified the efficacy of upgrade CRT according to initial pre-PPM LV systolic function. In other words, patients with preserved pre-PPM LVEF (PiCM upgrade) and those with reduced pre-PPM LVEF (non-PiCM upgrade) were all incorporated into the same group, increasing the heterogeneity of the upgrade group. On the contrary, we made an extra effort to break down the upgrade CRT group into the PiCM and non-PiCM upgrade subgroups; we investigated LVEF prior to PPM implantation and the presence of other causes of LVSD by a comprehensive review of patient medical records, including clinical information, echocardiography, ECG and other imaging and laboratory findings. We hypothesized that patients with PiCM would be better CRT responders than those in the other CRT groups, because, by definition, most of them had non-ischemic substrate and LBBB pattern, which are well-known predictors for favorable CRT response.[@B18][@B19][@B20][@B21] PiCM patients have other favorable features as well, including a greater degree of QRS narrowing after CRT upgrade.[@B19][@B20][@B22] and a shorter duration of HF than those treated by *de novo* CRT implantation.[@B22][@B23][@B24]

In our data, almost half of patients (46.7%) in the upgrade CRT group were classified as PiCM, according to the definition mentioned above in the Methods section. As compatible with our hypothesis, the PiCM upgrade group showed the greatest electro-mechanical reverse remodeling (*p*\<0.05) and the lowest rate of adverse events, including cardiac death, heart transplantation, and HF-related rehospitalization (*p*=0.059). We believe statistical significance could also be achieved for long-term clinical outcomes if a greater number of patients were followed for a longer period of time.

Although patients in the PiCM upgrade and non-PiCM upgrade groups shared similar manifestations of LV dilation, systolic dysfunction, and PPM dependency, clinical scenarios might have been quite different. In the PiCM upgrade group, conduction disorder requiring artificial pacing came first, and then LV dilatation and systolic dysfunction followed chronic RV pacing. However, in the non-PiCM upgrade group, pre-existing LV dilation and systolic dysfunction likely brought about a subsequent conduction disorder. Therefore, CRT could be a fundamental treatment for PiCM as it corrects the primary cause of LVSD.

There were several limitations of our study. As a single-center study of a small number of patients, there are concerns regarding selection bias. Especially, this study is underpowered to perform multivariate analysis for predictors of super-responder due to small patient number in upgrade groups. Furthermore, there was no standardized follow-up protocol, and retrospective data were collected for a relatively short follow-up duration. To overcome these limitations, we are also conducting analyses using nationwide, multicenter data.

The PiCM upgrade group showed better CRT response, compared to the non-PiCM upgrade and *de novo* groups, in terms of electrical and mechanical reverse remodeling. Therefore, CRT upgrade should be considered a fundamental therapy for patients with unexplained ongoing LVSD after PPM implantation.
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SUPPLEMENTARY MATERIALS
=======================

###### Supplementary Table 1

Indication for Pacemaker and Right Ventricular Pacing Burden in CRT Upgrade Patients

###### Supplementary Table 2

Changes in NYHA Class and Electrocardiographic and Echocardiographic Values after 6 Months

###### Supplementary Table 3

Clinical Outcomes

###### Supplementary Fig. 1

Change in New York Heart Association (NYHA) class between before cardiac resynchronization therapy (CRT) and 6 months after CRT. PiCM, pacing-induced cardiomyopathy.

![Study population. CHF, chronic heart failure; CRT, cardiac resynchronization therapy; PiCM, pacing-induced cardiomyopathy.](ymj-58-703-g001){#F1}

![Percent narrowing of QRS duration (A) and percent reduction in left ventricular end-systolic volume (B) 6 months after cardiac resynchronization therapy. ^\*^*p* value refers to the difference among the three groups by Kruskal-Wallis test. LVESV, left ventricular end-systolic volume; PiCM, pacing-induced cardiomyopathy.](ymj-58-703-g002){#F2}

![Echocardiographic responder and super-responder rates according to various echocardiographic criteria at 6 months after cardiac resynchronization therapy. LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; PiCM, pacing-induced cardiomyopathy.](ymj-58-703-g003){#F3}

![Comparison of survival curves for MACEs. MACEs, major adverse cardiovascular events; PiCM, pacing-induced cardiomyopathy.](ymj-58-703-g004){#F4}

###### Baseline Characteristics of Study Population

![](ymj-58-703-i001)

                                   PiCM upgrade (n=7)   Non-PiCM upgrade (n=8)   *De novo* (n=62)    *p* value^\*^             *p* value^†^   
  -------------------------------- -------------------- ------------------------ ------------------- --------------- --------- -------------- ---------
  Sex (male)                       4 (57.1)             5 (62.5)                 36 (58.1)           \>0.999         \>0.999   \>0.999        \>0.999
  Age (yr)                         62.1 (49.3--76.4)    62.4 (60.3--68.6)        66.7 (57.1--72.9)   0.934           0.694     0.819          0.791
  NYHA class                       3±0.0                3±0.0                    3±0.4               0.688           \>0.999   0.566          0.604
  Ischemic heart disease           0 (0)                3 (37.5)                 15 (24.2)           0.248           0.200     0.415          0.333
  Diabetes mellitus                1 (14.3)             2 (25.0)                 18 (29.0)           0.891           \>0.999   \>0.999        0.664
  Hypertension                     4 (57.1)             4 (50.0)                 34 (54.8)           \>0.999         \>0.999   \>0.999        \>0.999
  Atrial fibrillation              0 (0)                0 (0)                    4 (6.5)             \>0.999         \>0.999   \>0.999        \>0.999
  Heart failure duration (month)   9.2 (5.1--20.3)      28.7 (18.3--37.7)        34.6 (15.1--81.3)   0.092           0.121     0.420          0.042
  Current medication                                                                                                                          
   RAS blocker                     6 (85.7)             8 (100)                  55 (88.7)           0.813           0.467     \>0.999        \>0.999
   Diuretics                       6 (85.7)             7 (87.5)                 57 (91.9)           0.412           \>0.999   0.531          0.487
   Beta blocker                    3 (42.9)             5 (62.5)                 43 (69.4)           0.290           0.619     0.700          0.211
  Follow-up duration (month)       28.4 (6.2--42.4)     10.3 (6.1--20.2)         15.8 (8.7--21.3)    0.356           0.336     0.310          0.325
  Echocardiographic findings                                                                                                                  
   LVEF (%)                        22 (18--33)          26 (24--32)              22 (19--27)         0.051           0.536     0.011          0.623
   LVEDV (mL)                      200 (170--275)       210 (147--261)           260 (216--312)      0.032           0.955     0.048          0.054
   LVESV (mL)                      145 (114--226)       151 (108--195)           192 (164--252)      0.027           0.867     0.024          0.086
  Electrocardiogram findings                                                                                                                  
   QRS duration (msec)             184 (158--214)       190 (169--220)           161 (148--173)      0.003           0.779     0.002          0.037
   LBBB QRS morphology             6 (85.7)             8 (100)                  43 (69.4)           0.165           0.467     0.097          0.664
  LV lead position                                                                                                                            
   Lateral segment                 7 (100)              8 (100)                  59 (96.7)           \>0.999         \>0.999   \>0.999        \>0.999

PiCM, pacing-induced cardiomyopathy; NYHA, New York Heart Association; RAS, renin-angiotensin system; LV, left ventricular; LVEF, LV ejection fraction; LVEDV, LV end-diastolic volume; LVESV, LV end-systolic volume; LBBB, left bundle branch block.

Values are presented as median (interquartile range) or number of patients (%), except for NYHA class, which is presented as mean±standard deviation.

^\*^*p* value refers to the difference among the three groups by Kruskal-Wallis test, ^†^*p* value refers to the difference between two groups by Mann-Whitney U test; PiCM versus non-PiCM upgrade, non-PiCM upgrade versus *de novo*, PiCM versus *de novo* group, in that order. Lateral segment of LV lead position refers to anterolateral, lateral, or posterolateral coronary vein or lateral mid-LV epicardium.

###### Major Responder Rates and Response Rates According to LVEF Criteria 6 Months after Cardiac Resynchronization Therapy
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                                    PiCM upgrade (n=7)   Non-PiCM upgrade (n=8)   *De novo* (n=62)   Odds ratio (95% CI)^†^   *p* value   Odds ratio (95% CI)^‡^   *p* value
  --------------------------------- -------------------- ------------------------ ------------------ ------------------------ ----------- ------------------------ -----------
  Clinical responder (%)            7 (100)              7 (87.5)                 56 (90.3)          NA                       0.999       NA                       0.999
  Echocardiographic responder (%)   6 (85.7)             4 (50.0)                 33 (53.2)          0.17 (0.01--2.09)0       0.165       0.19 (0.02--1.67)        0.134
  Super-responder (%)               6 (85.7)             1 (12.5)                 20 (32.3)          0.02 (0.001--0.47)       0.014       0.08 (0.01--0.70)        0.023
  Any responder (%)\*               7 (100)              7 (87.5)                 57 (91.9)          NA                       \>0.999     NA                       \>0.999

LVEF, left ventricular ejection fraction; PiCM, pacing-induced cardiomyopathy; CI, confidence interval.

Values are presented as number of patients (%).

^\*^Any responder indicates the patients who meet the criteria of either clinical or echocardiographic responder, ^†^Indicates the value between the PiCM upgrade and non-PiCM upgrade group, ^‡^indicates the value between the PiCM upgrade and the *de novo* group.

###### Predictors for Super-Responder
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                                   Univariate analysis    Multivariate analysis                       
  -------------------------------- ---------------------- ----------------------- ------------------- -------
  Sex (female)                     0.52 (0.20--1.35)      0.180                   0.43 (0.14--1.32)   0.139
  Age (yr)                         1.00 (0.97--1.04)      0.933                                       
  NYHA class                       0.68 (0.16--2.87)      0.594                                       
  Ischemic cardiomyopathy          0.65 (0.20--2.06)      0.461                                       
  Diabetes mellitus                1.20 (0.42--3.39)      0.733                                       
  Hypertension                     1.07 (0.42--2.73)      0.896                                       
  PiCM upgrade                     14.0 (1.59--124)       0.018                   10.4 (1.08--99.4)   0.043
  Heart failure duration (month)   0.993 (0.983--1.003)   0.158                                       
  Current medication                                                                                  
   RAS blocker                     1.71 (0.32--9.09)      0.532                                       
   Diuretics                       0.70 (0.14--3.37)      0.652                                       
   Beta blocker                    0.38 (0.14--1.01)      0.053                   0.39 (0.12--1.22)   0.104
  Echocardiographic findings                                                                          
   LVEF (%)                        1.02 (0.94--1.11)      0.631                                       
   LVEDV (mL)                      0.99 (0.99--1.00)      0.056                                       
   LVESV (mL)                      0.99 (0.98--1.00)      0.070                   1.00 (0.99--1.01)   0.454
  Electrocardiogram findings                                                                          
   QRS duration (msec)             1.01 (0.99--1.02)      0.504                                       
   LBBB QRS morphology             4.12 (1.08--15.7)      0.038                   4.14 (0.95--18.1)   0.059

NYHA, New York Heart Association; PiCM, pacing-induced cardiomyopathy; RAS, renin-angiotensin system; LVEF, left ventricular ejection fraction; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LBBB, left bundle branch block.

Adjusted covariates included sex, PiCM, use of beta blocker, and QRS morphology.
